Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). The product is indicated ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI ™ (ustekinumab-aekn ...

STEQEYMA is available in both subcutaneous injection and intravenous infusion ... given the fact that Stelara ranks as one of the most expensive prescription drugs on the market," said Tom ...

On March 12, 2025, Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar ... FDA in December 2024 for subcutaneous injection or intravenous infusion in adult ...

Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection is expected to receive FDA approval in the first half of 2025. About Otulfi Otulfi (ustekinumab-aauz) is a human monoclonal ...

Celltrion is introducing Steqeymaq (ustekinumab-stba), which is a biosimilar ... It is available in both subcutaneous injection and intravenous infusion. "Chronic inflammatory diseases such ...

This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab ...